

PRESS KIT



Biofit

FOSTERING
INNOVATION
& TRANSFER

7TH
edition

4 & 5
DECEMBER
2018



Press Contact
Nadège JOLY
Event communication officer
03 28 55 90 60 | njoly@eurasante.com

www.biofit-event.com

 @BIOFIT_EVENT

#BioFIT2018

SUMMARY

EDITORIAL	3
KEY FIGURES	3
WITH OVER 1 300 REGISTERED PARTICIPANTS, BIOFIT IS ONE OF THE TOP 3 EUROPEAN LIFE SCIENCES CONVENTIONS	4
A unique position in Europe	4
Three regions with some of the most dynamic innovation ecosystems in France are joining forces to support BioFIT's growth	4
What's new on the BioFIT 2018 programme?	5
BIOFIT, LEADING EUROPEAN EVENT FOR EARLY-STAGE INNOVATIONS IN LIFE SCIENCES	7
Allowing academic organisations to showcase their knowledge	7
Fostering cooperation between academics, industry and start-ups	7
Facilitating access to early-stage financing for bioentrepreneurs.....	8
Responding to the growing need to identify CEOs and business developers.....	8
BIOFIT, THE PREFERRED EVENT VENUE FOR A GROWING NUMBER OF ORGANISATIONS	9
Partnering Day, by Boehringer Ingelheim.....	9
R&D dating for animal health and innovation, by SIMV	9
EGID Symposium by the Institut Européen Génomique du Diabète	9
European Diagnostic Clusters Alliance (EDCA)	9
Roche Day	10
Digital Systems & Life Sciences by SMMIL-E and Yncrea	10
IMODE.....	10
PATHACOV	10
BIOFIT 2018 AGENDA	11
THE STEERING COMMITTEE: INTERNATIONAL EXPERTS COMMITTED TO THE SUCCESS OF BIOFIT	12
ORGANISERS	13
SPONSORS	14
INSTITUTIONAL PARTNERS	14
SUPPORTERS	15
MEDIA PARTNERS	16
SAVE THE DATE - BIOFIT 2019	17

EDITORIAL

BioFIT has emerged as the leading European partnering event to source early-stage innovations and collaborative research capacities in Life Sciences and obtain funding for seed rounds.

We are delighted to welcome you to Lille for this seventh edition today and pleased to announce that BioFIT will be held in Marseille in 2019, in Strasbourg in 2020 and in Lille in 2021. This unique partnership between these three French ecosystems will enable BioFIT participants to discover different venues and destinations. Drawing on the strengths and assets of each region in which BioFIT is now based, the event is strengthening its position as a leading European partnering event to better provide its participants with a complete framework for exchanges fostering interactions and significantly increasing partnerships and funding opportunities.

We hope that you will fully take part in all the activities organised this year and that we will see you next year in Marseille on 10 and 11 December and in Strasbourg in December 2020 for even more meetings, deals and discoveries of early-stage innovations in Life Sciences!



Etienne Vervaecke
General Manager of **Eurasanté** and **the NHL Cluster**



Emilie Royere
General Manager of **Eurobiomed**



Marco Pintore
General Manager of **BioValley France**

KEY FIGURES

+1 300 registered participants
+35 countries represented
100 exhibitors
80 high-level speakers

WITH OVER 1 300 REGISTERED PARTICIPANTS, BIOFIT IS ONE OF THE TOP 3 EUROPEAN LIFE SCIENCES CONVENTIONS

BioFIT is now one of the top three European business conventions primarily due to its record figures: 1,300 participants registered for this seventh edition with 35 countries represented. However, there are also other reasons for its success, such as its unique positioning in Europe, focused on early-stage innovation in Life Sciences; its ability to bring together more groups every year to organise their own events during it - and even more so this year with a new host region; and its ability to develop its activities year after year to always remain connected to the needs and challenges of the sector.

A unique position in Europe

With the highest attendance rate of academics, TTOs and research institutes, BioFIT centralises academia-industry cooperation opportunities. BioFIT has taken on a whole new dimension becoming the European event for tech transfer and sourcing early-stage innovations stemming from public research institutes, academic spin-offs and emerging biotech companies. Together with major pharma, biotech and diagnostic companies, BioFIT is a platform to build partnerships for all public and private stakeholders. BioFIT is also the European marketplace for pre-seed, seed and Series A investments in Life Sciences.

Every year the event brings together delegates looking to enter into new R&D and innovation partnerships in Life Sciences. BioFIT is also an essential platform for project leaders and start-ups in the sector to meet seed and venture capital investment stakeholders.

'The conference was very good and a bit different to other conferences in terms of participants - more tech transfer, more early stage investors, more early stage companies.' Barbara Domayne-Hayman, CBO at AUTIFONY THERAPEUTICS LTD

'BioFIT supports individual entrepreneurial development and offers excellent international projection.' Maria Bobadilla, Senior Director, ROCHE

Three regions with some of the most dynamic innovation ecosystems in France are joining forces to support BioFIT's growth

A unique partnership between three powerful ecosystems (Sud Provence-Alpes-Côte d'Azur, Grand Est and Hauts-de-France regions) will be announced at BioFIT 2018.

Thanks to an unprecedented partnership between the NHL cluster, BioValley France and Eurobiomed competitiveness clusters, as well as Eurasanté and the local authorities of these three French regions, **BioFIT now has a foothold in Marseille (2019), Strasbourg (2020) and Lille (2021)**. As such, BioFIT will support the dynamics of industry and academic stakeholders in the sector and move towards the status of European leader in its sector: early-stage innovation in Life Sciences. Building on the strengths and assets of each region in which BioFIT is now organised, the event provides its participants with an ideal setting for exchanges fostering interactions and significantly increasing partnership and funding opportunities.

'When we were looking for a city to co-organise BioFIT with Lille, Strasbourg naturally established itself as a choice venue. Open to the international community and a region renowned for the quality of its universities, the effectiveness of its research promotion and tech transfer systems (e.g. Conectus Alsace) and the performance of its competitive cluster (BioValley France), Strasbourg offers a

complementarity with Lille. These aspects were the reason BioFIT was organised in Strasbourg as early as 2015, alternating with Lille. The BioFIT event in Marseille in 2019 represents a major step towards becoming the largest European event in the Life Sciences sector. The trio we are forming strengthens France's position as a leading stakeholder in international competition for early-stage financing of innovations in Life Sciences.' Etienne Vervaecke, General Manager of Eurasanté and the NHL Cluster

The Hauts-de-France region has a health sector with 1000 companies in nutrition and health for 30,800 employees and a value of more than 12 billion euros. The pharma-biotech-nutrition sub-sector alone employs 12,875 people and represents more than 50% of the regional turnover and 80% of the sector's export turnover. Some of the major names in the Hauts-de-France region include Genfit, LFB, Lesaffre, AlzProtect and Diagast.

The Sud Provence-Alpes-Côte d'Azur region is the second largest French centre for public scientific health research and the second French region for patent applications and clinical trials. It is also one of the most concentrated hospital networks in France with a vast array of research platforms and one of the most dynamic clinical, industrial and academic research activities in France. The region's research laboratories stand out in immuno-oncology with the Marseille Immunopôle cluster, infectious and tropical diseases and clinical microbiology hosted by the Institut Hospitalo-Universitaire Méditerranée Infection (IHU) and rare and orphan diseases and neurosciences.

The Grand Est region is a hotspot for Life Sciences, in a cross-border region characterised by a strong Franco-German-Swiss culture of cooperation and concentrating a dense population of renowned stakeholders in life and health sciences with seven Nobel Prize winners, leading universities, world-renowned research institutes and over 600 companies, ranging from innovative start-ups to giants in the pharmaceutical sector such as Lilly, Novartis, Sanofi and Roche. More generally, the region excels in biotechnology, medical devices and digital health.

'Strasbourg's Eurometropolis is located in the centre of the Franco-German-Swiss BioValley, characterised by a unique concentration of Life Sciences research institutes and companies. Partnerships between academic and industrial stakeholders are a tradition there. Therefore, hosting an international event, such as BioFIT, dedicated to technology transfer and the creation of economic activities based on public research, made perfect sense. BioFIT enables researchers and companies from the Grand Est to enter into partnerships with partners from all over the world, thus contribute to creating value for the region.' Marco Pintore, General Manager of BioValley France

'By holding an annual international event bringing together over 1,300 high-level stakeholders, BioFIT is a unique opportunity for Marseille and the region to promote its ecosystem and improve its economic and scientific attractiveness. This strategy should attract exogenous companies to our region and significantly increase the amount of private capital injected into companies in our sector thanks to the attraction of foreign funds (90 % of capital investors attending BioFIT are not French). We are convinced that BioFIT will help to confirm Marseille's position on the map of European hotspots in biotech and health.' Emilie Royere, General Manager of Eurobiomed

What's new on the BioFIT 2018 programme?

A conference programme that aims to widen the scope of the topics discussed

This year, BioFIT is devoting part of its conference programme to **investment trends, pre-seed, seed and Series A in the field of Life Sciences**. It also focuses on showcasing new categories of stakeholders financing early-stage projects. Over the last four conferences, the SIMV (professional organisation that unites and represents veterinary medicines companies in France) has brought together industries and academics from the animal health sector at the convention. Participants will be able to attend sessions hosted by animal health product suppliers as well as conferences where speakers will be exploring *One Health*, which could potentially support comparative medicine and, therefore, cross-industry cooperation.

All in all, over 80 international speakers with a variety of backgrounds from academia, industry, TTOs and investors will be discussing issues and trends in the field of Life Sciences. Conference speakers include: Caroline Barelle, **Elasmogen** (UK), Gábor M. Lamm, **EMBLEM Technology Transfer** (DE), Tiina Urv, the **National Institutes of Health** (US), Alain Chevallier, **Truffle Capital** (FR).

'The BioFIT conference featured lively speakers, an exciting opportunity for attendees from around the world.' Garold Breit, Director, Technology Business Development, City of Charleston

Responding to the increasing need to find CEOs and business developers

The BioFIT 2017 plenary conference's theme was *How can we overcome the shortage of bioentrepreneurs in Europe?* Over 300 people attended, reflecting the importance of this issue for the development of Life Sciences. To respond to this concern of a growing number of stakeholders, BioFIT 2018 has introduced a new event which capitalises on the secret of its success, the partnering tool, thanks to which some 1 000 deals were generated in 2017. Now, for the 2018 conference, the partnering platform will be **connecting bioentrepreneurs and business developer with much sought after backgrounds with start-ups and companies looking for them**. To increase the visibility of this new opportunity, BioFIT will be partnering with a Walloon business incubator (WBC Incubator) to organise the first *Would-be CEO Networking Lunch*.

BioFIT is the preferred event venue for a growing number of organisations

Every year, BioFIT hosts more events with complementing themes. This year, the following organisations will be present:

- The **European Institute of Genomics and Diabetes** (EGID), with its biennial symposium on *The gut, incretins and diabetes*,
- The **SMMIL-E project** (Organ on Chip for cell therapy and drugs screening)
- **Roche**, with a day of conferences about innovation in health
- **Boehringer Ingelheim**, with a day dedicated to one-to-one meetings.

Finally, proof that BioFIT is the industry's European point of reference when it comes to partnering events is that it is now being chosen by many European consortia as the venue for their meetings. This year, they include the **IMODE project** (delivery of subcutaneous pharmaceutical molecules), the **European Alliance of Diagnostic Clusters**, with a session about new European regulations regarding in-vitro diagnostics, and the **PATHACOV project** (early diagnosis of human pathologies by analysing volatile organic compounds in exhaled air).

BIOFIT, LEADING EUROPEAN EVENT FOR EARLY-STAGE INNOVATIONS IN LIFE SCIENCES

Allowing academic organisations to showcase their knowledge

Largely supported by ambitious investment and support programmes led by the French government and local authorities, French academic research in health, the vocation of which is to generate knowledge that meets societal health challenges, is one of the most prolific worldwide. However, the funding models of public research laboratories have evolved in recent years, sometimes partly subject to the achievement of objectives in terms of cooperation with private economic stakeholders, whether start-ups, SMEs or industrial groups.

Competitiveness clusters, such as the Nutrition-Health-Longevity Cluster, BioValley France and Eurobiomed, help these types of stakeholders to work in a more collaborative way as sources of innovation for the market. BioFIT is the emblematic event organised by this trio of organisations offering, at the same time and place, the possibility to establish contacts with a view to cooperation in the field of Life Sciences.

Research institutes and technology transfer companies see BioFIT as the ideal event to showcase their intellectual property and collaborative research abilities. Private stakeholders, SMEs and companies can draw on this reservoir of innovations and technologies to design new solutions, products and services for the health market and respond to new uses.

'BioFIT seemed like THE one-stop shop for making excellent contacts with pharma. The environment is great to promote discussions and productive meetings.' Rui Sousa, TTO, University of Minho

'BioFIT is a highly relevant event to promote new technologies and/or initiate or even boost their development.' Alice Nicolas, CNRS (FR)

Fostering cooperation between academics, industry and start-ups

French fundamental health research is developing practical applications by increasing partnerships with companies. Over the past ten years, academics, industry and start-ups have entered into partnerships because they have understood that innovation comes from cooperation to draw on the complementarity of resources and skills.

BioFIT provides a framework for exchanges fostering cooperation between public research and the private sector by strengthening the links between them. This virtuous alliance, for the benefit of the patient/individual, is particularly adapted to the specificities of the sector, with, on the one hand, researchers, clinicians and start-ups involved in helping innovative health solutions to emerge, and, on the other hand, a private sector in search of technologies to meet or even anticipate the market needs. In this context, BioFIT is the ideal platform for technology transfer serving health innovation.

In terms of cooperation, partnership innovation is also important. BioFIT 2018 conference will allow participants to learn about new models of cooperation between universities and industry. During round tables, experts will discuss, for example, the use of artificial intelligence in Life Sciences, which influences drug discovery processes at all stages and can influence the structure of collaborative research.

Many initiatives, often jointly undertaken by universities, venture capital firms, businesses, charities and governments, aim to close the gap between a promising academic result and a transferable asset. A full series of round tables will provide BioFIT participants with many examples of what are called maturation or pre-seeding systems.

Key industry stakeholders will be present at BioFIT 2018, including Lilly, Roche, Merck, Boehringer Ingelheim, Bayer, GSK-Glaxosmithkline, LFB, Novo Nordisk, Johnson&Johnson, Ipsen Innovation, Sanofi and Pfizer.

In total in 2017, 2,700 one-to-one meetings were held during the business convention and some 1,000 licensing opportunities were identified. Over the previous years (2015 and 2016), 1,000 deals (35 % collaborative research projects, 30 % licensing agreements, 15 % investments and 20 % services) were generated over the medium-term following the event.

'One month before the event, you can already schedule your meetings to optimise your time on-site and thus meet many potential partners. This is a real asset.' Tereza Brezinova, University of Chemistry and Technology of Prague (CZ)

'BioFIT has allowed me to make more business meetings than any other event I have ever attended', Michael Midmer, EC, Zuraca Therapeutics, (CA)

Facilitating access to early-stage financing for bioentrepreneurs

BioFIT is the marketplace for Life Sciences start-ups to finance their R&D programmes and development.

The *Start-up Slams* pitch competition is an opportunity for the most promising European start-ups in the sector to reach out to 80 investors and initiate discussions with a view to raising funds on Europe's leading market place for seed capital in Life Sciences.

This year, Start-up Slams are organised in several categories:

- Therapeutics - cancer | Immuno-oncology
- Delivery | Discovery | Research tools
- Production tools
- Diagnosis
- Therapeutic - other indications.

Among the 300 start-ups participating in BioFIT 2018, over 80 applications to pitch at *the Start-up Slams* were received; only the 20 most promising, chosen by a panel of international experts, were given the opportunity to present their project to a panel of experts, allowing them to benefit from speed-mentoring and visibility with potential investors and industrial partners.

BioFIT also devotes a portion of its conference programme to current events and trends in investment, seed capital and venture capital in Life Sciences and is committed to presenting new categories of agents financing early-stage projects.

Responding to the growing need to identify CEOs and business developers

For the first time, BioFIT makes it possible to identify scarce profiles that are nevertheless essential for the Life Sciences sector in its seventh edition. The profiles of CEOs, Business Developers, etc. are profiles that industry stakeholders are struggling to identify but they are decisive for the development of companies of all sizes.

To meet this need, BioFIT has organised its first *Would-be CEO Networking Lunch* in partnership with Walloon incubator WBC. This networking lunch is designed to facilitate the identification of *Would-be CEOs* for start-ups and companies looking for these profiles. In order to extend this networking time, these CEO profiles will also be identifiable on the partnering platform available throughout the business convention.

'It was to meet the demand of the sector's stakeholders that we had the idea of creating an event dedicated to putting scarce profiles in the biotechnology sector (CEOs, business developers, etc.) and companies looking for these key human resources into contact with each other. This Would-be CEO networking lunch and its extension via the business convention platform thus reinforces BioFIT's offer to support stakeholders in the sector in all areas of innovation development.' Etienne Vervaecke, General Manager of BioFIT

BIOFIT, THE PREFERRED EVENT VENUE FOR A GROWING NUMBER OF ORGANISATIONS

Full details of each hosted event are presented in the BioFIT 2018 programme.

Partnering Day, by Boehringer Ingelheim

In recent years, Boehringer Ingelheim has increasingly opened up to external cooperation to develop new medicinal products. As such, in partnership with the NHL cluster and in cooperation with BioFIT, Boehringer Ingelheim is organising a partnership day for the first time in France, where it will be possible to meet members of the group's R&D and business development teams to discuss possible partnership opportunities.

R&D dating for animal health and innovation, by SIMV

The Syndicat de l'Industrie du Médicament et du réactif Vétérinaires (SIMV) has organised meetings between veterinary departments, industry, medical research and biotechnology companies during the last four BioFIT events. This year, participants will also be able to attend pitch sessions proposed by animal health suppliers and conferences where speakers will explore common points between animal and human environments supporting comparative medicine and, therefore, inter-sectoral cooperation.

'BioFIT focuses on animal health, which is clearly lacking in most other events.' Rudiger Raue, Zoetis (BE)

EGID Symposium by the Institut Européen Génomique du Diabète

BioFIT will be hosting the fifth EGID Symposium during its first day. More than 150 participants registered for this Symposium will discover five international speakers talking about *The gut, incretins, diabetes*:

- Gilles Mithieux, U1213 INSERM, Université C Bernard, Lyon, France – Gut-Brain Glucose Signalling in the Control of Energy Homeostasis;
- Roy Taylor, Newcastle University, Newcastle upon Tyne, UK – Food and Type 2 Diabetes: Restoring the Milieu Interieur;
- Rachel Batterham, University College London, UK – Insights From Bariatric Surgery;
- Nikolaus Marx, University Hospital, Aachen, Germany – Incretins, Diabetes and Cardiovascular Disease;
- Aimo Kannt, Sanofi Diabetes Research, Germany – Therapeutic Potential of Multi-Incretin Therapy – From mice to men.

European Diagnostic Clusters Alliance (EDCA)

The European Diagnostic Clusters Alliance (EDCA) has organised a round table to discuss the contribution of AI to next-generation diagnostics.

EDCA has the following purposes:

- promote competitiveness of European industry in the field of medical diagnosis. The association will enhance synergies between academic research, clinical research, health authorities and diagnostic companies;
- help European SMEs develop in medical diagnostics;
- promote the development of diagnostic clusters and competitiveness clusters in Europe;

- promote cooperation between diagnostic clusters (inter-cluster) in order to help build European collaborative projects.

Roche Day

The pharmaceutical company Roche is organising a forum-debate on *Innovation in health in the Hauts-de-France region*.

It will address five main themes: Experience sharing of the Hauts-de-France's Institutions, Connected Medicine, Big Data, Access & Funding for Innovation, Rights and Ethics.

Digital Systems & Life Sciences by SMMIL-E and Yncrea

Created to accelerate the transfer of innovative technologies in Life Sciences, the *Digital Systems & Life Sciences* Chair offers original approaches for the diagnosis and follow-up of the patient in different types of pathology.

Within Eurasanté, the *Digital Systems & Life Sciences* Chair is an ecosystem conducive to start-up development. Based on bioMEMS (Microsystem for Biology and Health) and Artificial Intelligence (AI) expertise, this new Chair offers technological support to young companies wishing to take advantage of these new opportunities. For its launch, a series of highlights led by renowned international researchers will be offered throughout the afternoon: workshops, round table, networking, etc. In the presence of Thierry Occre, Director of ISEN Lille, this event will close with a press conference presenting the new Yncrea Hauts-de-France Chair, its objectives and missions.

IMODE

IMODE has organised its second annual convention during BioFIT with a morning of conferences and participation in the BioFIT one-to-one meetings during the afternoon.

IMODE is a collaborative research project for multicomponent pharmaceutical products (coamorphous and co-crystals) and medical devices loaded with bioactive molecules.

Launched in 2016, the IMODE project is funded by the European Interreg 2 Seas programme and co-financed by the European Regional Development Fund (ERDF).

PATHACOV

Led by Professor Régis Matran (Lille University Hospital), the European project PATHACOV has organised its launch event during BioFIT 2018.

The project aims to develop early diagnosis of human diseases through the analysis of VOCs in exhaled air. The challenge is to develop and implement an innovative methodology in the field of health and, in particular, in the early diagnosis of bronchopulmonary cancers.

The project will provide populations on both sides of the border, regardless of socio-economic level, with access to a simple, non-traumatic method for early detection of bronchopulmonary cancer and other human diseases.

Launched in 2018, the PATHACOV project is funded by the Interreg France-Wallonia-Flanders programme with the support of the European Regional Development Fund (ERDF).

BIOFIT 2018 AGENDA

DAY ONE Tuesday, December 4 th			DAY TWO Wednesday, December 5 th		
Conferences and roundtable discussions		Pitch sessions	Conferences and roundtable discussions		Pitch sessions
8:30 am - 9:30 am: NAME BADGE PICKUP & WELCOME COFFEE					
9:30 am - 11:00 am: ARTOIS 1 Agnostic or pure players in the biotech sector. Who is becoming prominent in the early-stage financing rounds?	9:30 am - 11:00 am: ARTOIS 2 Artificial Intelligence to speed up drug discovery. The revolutionary road to advancing innovation	9:30 am - 11:00 am: INNOVAREA Licensing Opportunity Presentations <small>THERAPEUTICS - CNS VACCINES INFECTIOUS DISEASES</small>	9:30 am - 10:30 am: ARTOIS 1 What roles do academic institutions or TTOs play as shareholders in spinoffs?	9:30 am - 10:30 am: ARTOIS 2 How can common pathways in human and animal health set up a new era for collaborations?	9:30 am - 10:30 am: INNOVAREA Start-up Slams <small>DELIVERY DISCOVERY RESEARCH TOOLS PRODUCTION TOOLS</small>
11:00 am - 11:30 am: NETWORKING BREAK					
11:30 am - 1:00 pm: PASTEUR AMPHITHEATRE PLENARY SESSION Seed funds crossing borders: How far and how fast is the early-stage investment market in Biotech globalising?					
1:00 pm - 2:30 pm: LUNCH					
2:30 pm - 4:00 pm: ARTOIS 1 Beyond shared R&D means of pharma and academic institutions, common strategies for collective success	2:30 pm - 4:00 pm: ARTOIS 2 What are the recent initiatives to ensure more mature assets of academic origin?	2:30 pm - 4:00 pm: INNOVAREA Start-up Slams <small>THERAPEUTICS - CANCER IMMUNO-ONCOLOGY</small>	2:30 pm - 3:30 pm: ARTOIS 1 How available to biotech start-ups have philanthropic and other sources of soft funding become today?	2:30 pm - 3:30 pm: ARTOIS 2 Is externalising the tech transfer function for academic institutions a key to succeed?	2:30 pm - 3:30 pm: INNOVAREA Start-up Slams <small>DIAGNOSTICS THERAPEUTICS - OTHER INDICATIONS</small>
4:00 pm - 4:30 pm: NETWORKING BREAK					
4:30 pm - 6:00 pm: ARTOIS 1 Thinking of the exit scenario to shape a biotech start-up of its first steps. Which model for which term of exit?		4:30 pm - 6:00 pm: INNOVAREA Licensing Opportunity Presentations <small>THERAPEUTICS - CANCER DIAGNOSTICS - CANCER</small>			
6:30 pm: BIOPARTY					

TRACK 1: Best practices in academia-industry R&D collaborations

TRACK 2: Marketing and licensing early stage assets

TRACK 3: Early-stage innovation: Identify the right funding sources

One-to-one meetings

Biofit BIOTECH INNOVATION & TRANSFER

AGENDA | HOSTED EVENTS

ROOMS	Dec. 3 rd	December 4 th			
	ROTTERDAM	HAINAUT	EUROTOP	REMBRANDT	VAN GOCH
8:30 am	Boehringer Ingelheim Partnering Day	SMILE Event	Lipid Symposium	Imode Convention	Roche Day
9:00 am			WELCOME COFFEE	WELCOME COFFEE	WELCOME COFFEE
9:30 am			Introduction	IMODE best practices	Introduction
10:00 am			Gut-Brain glucose signaling in the control of energy homeostasis	Testing of New Drugs & Devices for Regulatory Approval	Experience sharing of the Haus-de-France's institutions
10:30 am			Food and type 2 diabetes: Restoring the Milieu Interieur	Electrospinning approach for drug delivery	
10:45 am			Insights from bariatric surgery	Nanostructured materials: The next generation of active stents/vessels	
11:00 am				BREAK	BREAK
11:30 am			DRINK	Tissue Engineering approach	Turning the spotlight on start-ups
12:00 pm	LUNCH		POSTER SESSION	Regenerative medicine approach	Connected medicine
1:00 pm	1:1 Partnering Meetings			Cardiovascular Disease, Restenosis and Thrombosis	
1:30 pm		WELCOME	LUNCH	LUNCH	LUNCH
2:00 pm					
2:30 pm	1:1 Partnering Meetings	WORKSHOP on "Organ on Chip for cell therapy and drugs screening"	Incretins, diabetes and CV disease	Big data	Big data
3:15 pm			Therapeutic potential of multi-incretin therapy - from mice to men	Access and funding for innovation	Access and funding for innovation
4:00 pm	Company Presentations	BREAK	BREAK	BREAK	BREAK
4:30 pm	Panel Discussion: Collaborative Research and Partnering with Boehringer Ingelheim	ROUND TABLE: What curriculum for Research or Education on Digital Systems and Life Sciences	Best paper award	Right and ethics	Right and ethics
5:00 pm		Presser of the "Treaty Chair"	Conclusion & Invitation to the cheese and wine cocktail	Key learning points	Key learning points
5:30 pm	NETWORKING RECEPTION	PRESS CONFERENCE		Conclusion	Conclusion
5:45 pm					
6:30 pm	WELCOME RECEPTION				

AGENDA | HOSTED EVENTS

	Dec. 4 th	December 5 th	
	EXHIBITION AREA	RUBENS 1	HAINAUT
9:00 am	SIMV R&D dating	EDCA Roundtable	PATHACOV Symposium
9:30 am			WELCOME COFFEE
10:30 am	R&D dating for animal health and innovation		Introduction to the filtering from Wellcome-Vlaanderen programme
11:00 am		Roundtable: AI to next-generation diagnostics	PATHACOV project and patient impact
12:30 pm	R&D dating for animal health and innovation		BREAK
1:00 pm		LUNCH	Specific markers VOC (Volatile Organic Compounds)
2:00 pm			Innovative tools for early diagnosis
2:30 pm	REMBRANDT Animal Health R&D Service Presentations		
4:00 pm	Award Ceremony of the AFVAC*		
4:30 pm	R&D dating for animal health and innovation		
6:30 pm	BIOPARTY		

* AFVAC: French Association of Veterinarians for Pets

THE STEERING COMMITTEE: INTERNATIONAL EXPERTS COMMITTED TO THE SUCCESS OF BIOFIT

PHARMA, BIOTECH	ACADEMIA, TTOs	ASSOCIATIONS, CLUSTERS & LAW FIRMS	
 <p>Maria Bobadilla SENIOR DIRECTOR, EXTENDING INNOVATION NETWORK, ROCHE 🇨🇪</p>	 <p>Hervé Ansanay OPERATIONS DIRECTOR, SATT AXLR 🇫🇷</p>	 <p>Nicolas Carboni PRESIDENT, RÉSEAU C.U.R.I.E. 🇫🇷</p>	
 <p>Adrian Carter CORPORATE VICE PRESIDENT AND GLOBAL HEAD OF DISCOVERY RESEARCH COORDINATION, BOEHRINGER INGELHEIM 🇩🇪</p>	 <p>Jürgen Bauer DEPUTY MANAGING DIRECTOR, EMBLEM TECHNOLOGY TRANSFER 🇩🇪</p>	 <p>Barbara Freischem MANAGING DIRECTOR, EBE - EUROPEAN BIOPHARMACEUTICAL ENTERPRISES 🇪🇺</p>	
 <p>Sami Chtourou EXECUTIVE VICE PRESIDENT INNOVATION & SCIENTIFIC AFFAIRS, LFB 🇫🇷</p>	 <p>Garold Breit DIRECTOR, TECHNOLOGY BUSINESS DEVELOPMENT, CITY OF CHARLESTON 🇺🇸</p>	 <p>Yohan Grosjean COMMUNICATION OFFICER, AFSSI - THE FRENCH ASSOCIATION OF OUTSOURCING AND INNOVATIVE COMPANIES 🇫🇷</p>	
 <p>Florence Dal Degan R&D INNOVATION SOURCING DIRECTOR, NOVO NORDISK 🇩🇰</p>	 <p>Jean-Luc Chagnaud HEALTHCARE BUSINESS DEVELOPMENT MANAGER & INTELLECTUAL PROPERTY MANAGER, AQUITAINE SCIENCE TRANSFERT 🇫🇷</p>	 <p>Jean-Louis Hunault PRESIDENT, SIMV - THE FRENCH ASSOCIATION OF THE ANIMAL HEALTH INDUSTRY 🇫🇷</p>	
 <p>Guy Hélin CEO, SYNGULON 🇫🇷</p>	 <p>Anthony Daccache BUSINESS DEVELOPER, SATT NORD 🇫🇷</p>	 <p>Marco Pintore GENERAL MANAGER, BIOVALLEY FRANCE 🇫🇷</p>	
 <p>Stephan Lensky CHIEF OPERATING AND CHIEF BUSINESS OFFICE, EPIMAB BIOTHERAPEUTICS 🇮🇱</p>	 <p>Lilla Farkas HEAD, OFFICE OF THE MANAGING DIRECTOR, RESEARCH COORDINATOR, MPI-CBG, MAX PLANCK INSTITUTE OF MOLECULAR CELL BIOLOGY AND GENETICS 🇩🇪</p>	 <p>Christian Policard MEMBER OF THE BOARD, CHAIRMAN OF THE BUSINESS DEVELOPMENT SUB-COMMITTEE, FRANCE BIOTECH 🇫🇷</p>	
 <p>Sabrina Lesage STRATEGIC ALLIANCES MANAGER, PFIZER 🇺🇸</p>	 <p>Esther Lange INDUSTRY LIAISON MANAGER, ASCENION 🇩🇪</p>	 <p>Emilie Royere GENERAL MANAGER, EUROBIOMED 🇫🇷</p>	
 <p>Marie-Ange N'Zoutani DIRECTOR, EXTERNAL INNOVATION DRUG DISCOVERY, BUSINESS DEVELOPMENT & LICENSING, SANOFI 🇫🇷</p>	<th style="background-color: #f9e79f;">INVESTORS</th> <td>  <p>Cécile Théard-Jallu PARTNER ATTORNEY, DE GAULLE FLEURANCE & ASSOCIÉS 🇫🇷</p> </td>	INVESTORS	 <p>Cécile Théard-Jallu PARTNER ATTORNEY, DE GAULLE FLEURANCE & ASSOCIÉS 🇫🇷</p>
 <p>Frédéric Scaërou SENIOR DIRECTOR, HEAD OF EXTERNAL INNOVATION EUROPE AND ASIA, IPSSEN INNOVATION 🇫🇷</p>	 <p>Frank Hensel PRINCIPAL, HIGH-TECH GRÜNDERFONDS 🇩🇪</p>	 <p>Etienne Vervaecke GENERAL MANAGER, EURASANTÉ & NHL CLUSTER 🇫🇷</p>	
 <p>Nadine Weisslinger-Darmon MEDICAL DIRECTOR SPECIALTY PRODUCTS, CLINICAL RESEARCH AND ACADEMIC ALLIANCES, OSK 🇫🇷</p>	 <p>Jérôme Majoie GENERAL MANAGER, FOUNDATION FOURNIER-MAJOIE 🇫🇷</p>		
	 <p>Sara Nunez-Garcia BIOTECH INVESTOR, FORMERLY PRINCIPAL WITH SOFINNOVA PARTNERS 🇫🇷</p>		
	 <p>Zhizhong Yao ASSOCIATE, CAPITAL FUNDS, SOFINNOVA PARTNERS 🇫🇷</p>		
	 <p>Loffi Yelles Chaouche PARTNER, THEODORUS FUND 🇫🇷</p>		

ORGANISERS



Eurasanté is an incubator, a technology transfer tool and a cluster manager in the biotech, medtech, nutrition and healthcare fields in Northern France. It assists French and foreign companies, entrepreneurs, scientists and clinicians with their innovations and development projects.

The regional network includes over 1,000 companies working in Life Sciences and Healthcare. The Health field in the Hauts-de-France region has a total of 30,800 employees. Eurasanté also promotes the Eurasanté Bio-business Park which hosts 7 hospitals, 4 universities, 7 specialised schools, 170 companies and 50 laboratories. Eurasanté also organises four international partnering events intended to increase and improve interaction between academia and industry (BioFIT, NutrEvent, MedFIT, AgeingFit).



The Nutrition Health Longevity (NHL) Cluster is a dynamic network at the intersection of health, biotechnology and nutrition.

The NHL Cluster aims to connect academia and industry partners around R&D projects. It focuses on the prevention and treatment of lifestyle-related diseases, such as metabolic and cardiovascular pathologies, neurodegenerative diseases and inflammatory bowel diseases. Its goal is to bring together and support stakeholders from the health and food sectors in designing, developing and financing their future products and processes.



Competitiveness cluster since 2005, BioValley France aims to federate, develop and promote the healthcare sector in the Grand Est region through innovation. The cluster is based on a dynamic network of companies, a leading academic and clinical research, as well as an integrated network of key stakeholders in innovation. BioValley France supports its members in their R&D Innovation approach and gives them access to high value-added expertise, in a market approach. The Cluster contributes to the networking of the various actors and the creation of regional, national and international partnerships. Finally, BioValley France actively participates in the territory's structuring projects, such as Nextmed, which aims to create a Medical Technologies campus in Strasbourg that hosts an entire ecosystem of excellence dedicated to the development of tomorrow's health technologies.



Founded in 2009 by regional stakeholders, EUROBIOMED is a Life Science cluster based in Southern France. Over 285 innovative biotech and medtech companies, as well as leading research institutes, hospitals and universities are members. We lead regional initiatives and help our member businesses and research institutes to innovate, finance, develop and achieve their scientific and business objectives to ultimately improve the treatment and the lives of patients.

Eurobiomed tops European rankings in all stages of innovation: education, basic, translational and clinical research, technological innovation centres, start-ups and industrial success stories. Among Eurobiomed's main assets are the number of people involved, the quality of the network and the mutual trust of its members, which reinforces interactions and facilitates cooperation.

SPONSORS

GOLD SPONSOR



SILVER SPONSOR



BRONZE SPONSORS



CONTRIBUTING SPONSORS



INSTITUTIONAL PARTNERS



MEDIA PARTNERS



Every year, BioFIT builds partnerships with media in the sector.

If your media not one of our partners yet, contact us now for a tailor-made partnership offer.

Nadège Joly

Event Communication Officer

+33(0)3 28 55 90 60 | njoly@eurasante.com

S A V E T H E D A T E



Biofit FOSTERING INNOVATION & TRANSFER

The leading European partnering event for early-stage deals and investment rounds in the Life Sciences field

NEW DESTINATION
MARSEILLE
FRANCE
8th edition **DECEMBER 10 & 11 2019**

1,200
delegates 

35+ 
countries represented

Organised by:



Institutional partners:

